Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical versus intravenous tranexamic acid for bleeding reduction in head and neck surgery
IRCT20231124060157N1Phase 3Completed
- Sponsor
- Mashhad University of Medical Sciences
- Start
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tranexamic acid in Malignant neoplasm of head (3 arms), sponsored by Mashhad University of Medical Sciences. Primary endpoints: Postoperative bleeding volume, Need for blood transfusion and 1 more. Started Feb 2024; status: completed.
02
Drugs
tranexamic acid
03
Conditions
Malignant neoplasm of head
Beyond the preview
Go deeper on IRCT20231124060157N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20231124060157N1.